{
    "ticker": "GEMD",
    "name": "Gemini Therapeutics, Inc.",
    "description": "Gemini Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for patients with retinal diseases. Founded in 2015 and based in Cambridge, Massachusetts, Gemini is dedicated to advancing the field of ophthalmology with an emphasis on genetic and cellular therapies. The company's lead product candidate, GEM103, is a gene therapy designed to address the underlying causes of dry age-related macular degeneration (AMD), a leading cause of vision loss in older adults. By employing cutting-edge gene-editing technologies, Gemini aims to restore vision and improve the quality of life for patients suffering from retinal diseases. The company's unique approach leverages its proprietary platform to enable the development of targeted therapies that can specifically address the genetic mutations responsible for these conditions. With a strong pipeline of product candidates and collaborations with leading research institutions, Gemini Therapeutics is positioned to become a leader in the field of retinal therapeutics, committed to transforming the treatment landscape for patients worldwide.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Cambridge, Massachusetts, USA",
    "founded": "2015",
    "website": "https://www.geminitherapeutics.com",
    "ceo": "Mark D. H. S. Karp",
    "social_media": {
        "twitter": "https://twitter.com/geminitherapeutics",
        "linkedin": "https://www.linkedin.com/company/gemini-therapeutics"
    },
    "investor_relations": "https://investors.geminitherapeutics.com",
    "key_executives": [
        {
            "name": "Mark D. H. S. Karp",
            "position": "CEO"
        },
        {
            "name": "Susan A. K. Karp",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Gene Therapy",
            "products": [
                "GEM103"
            ]
        }
    ],
    "seo": {
        "meta_title": "Gemini Therapeutics, Inc. | Innovative Retinal Disease Therapies",
        "meta_description": "Explore Gemini Therapeutics, Inc., a leader in gene therapy for retinal diseases. Discover their innovative approach to treating AMD and other conditions.",
        "keywords": [
            "Gemini Therapeutics",
            "Gene Therapy",
            "Retinal Diseases",
            "Ophthalmology",
            "AMD",
            "Biotechnology"
        ]
    },
    "faq": [
        {
            "question": "What is Gemini Therapeutics known for?",
            "answer": "Gemini Therapeutics is known for developing innovative gene therapies for retinal diseases, particularly dry age-related macular degeneration."
        },
        {
            "question": "Who is the CEO of Gemini Therapeutics?",
            "answer": "Mark D. H. S. Karp is the CEO of Gemini Therapeutics, Inc."
        },
        {
            "question": "Where is Gemini Therapeutics headquartered?",
            "answer": "Gemini Therapeutics is headquartered in Cambridge, Massachusetts, USA."
        },
        {
            "question": "What is the lead product of Gemini Therapeutics?",
            "answer": "The lead product candidate is GEM103, a gene therapy targeting dry age-related macular degeneration."
        },
        {
            "question": "When was Gemini Therapeutics founded?",
            "answer": "Gemini Therapeutics was founded in 2015."
        }
    ],
    "competitors": [
        "NVDA",
        "SNY",
        "RGEN"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "REGN",
        "BMY"
    ]
}